Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Harvard Business School
Colorcon
Boehringer Ingelheim
Merck

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,410,656

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,410,656 protect, and when does it expire?

Patent 7,410,656 protects PICATO and is included in one NDA.

This patent has nineteen patent family members in fifteen countries.

Summary for Patent: 7,410,656
Title:Anti-cancer compounds
Abstract: This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
Inventor(s): Aylward; James Harrison (St. Lucia, AU)
Assignee: Peplin Research Pty. Ltd. (Fortitude Valley, AU)
Application Number:10/896,811
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,410,656
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,410,656

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-001 Jan 23, 2012 AB RX Yes Yes   Start Trial   Start Trial TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS   Start Trial
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-002 Jan 23, 2012 AB RX Yes Yes   Start Trial   Start Trial TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,410,656

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPO 8640Aug 19, 1997

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Merck
Boehringer Ingelheim
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.